このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

iRhythm Technologies マネジメント

マネジメント基準チェック /24

iRhythm Technologies'の CEO はQuentin Blackfordで、 Oct2021年に任命され、の在任期間は 2.67年です。の年間総報酬は$ 16.60Mで、 4.1%給与と95.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.23%を直接所有しており、その価値は$ 6.92M 。経営陣と取締役会の平均在任期間はそれぞれ2年と6.9年です。

主要情報

Quentin Blackford

最高経営責任者

US$16.6m

報酬総額

CEO給与比率	4.1%
CEO在任期間	2.7yrs
CEOの所有権	0.2%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	6.9yrs

経営陣の近況

Recent updates

CEO報酬分析

iRhythm Technologies の収益と比較して、Quentin Blackford の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$130m
Dec 31 2023	US$17m	US$677k	-US$123m
Sep 30 2023	n/a	n/a	-US$105m
Jun 30 2023	n/a	n/a	-US$99m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$8m	US$650k	-US$116m
Sep 30 2022	n/a	n/a	-US$128m
Jun 30 2022	n/a	n/a	-US$131m
Mar 31 2022	n/a	n/a	-US$124m
Dec 31 2021	US$10m	US$163k	-US$101m

報酬と市場: Quentinの総報酬 ($USD 16.60M ) は、 UK市場 ($USD 2.46M ) の同規模の企業の平均を上回っています。

報酬と収益: Quentinの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Quentin Blackford (45 yo)

2.7yrs

在職期間

US$16,595,149

報酬

Mr. Quentin S. Blackford serves as an Independent Director of Paragon 28, Inc. since August 1, 2022. He serves as President and Chief Executive Officer since October 04, 2021 and serves as Director at iRhy...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Quentin Blackford	President	2.7yrs	US$16.60m	0.23% $ 7.5m
Brice Bobzien	Chief Financial Officer	1.8yrs	US$5.28m	0.0085% $ 276.6k
Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	2.2yrs	US$5.32m	0.011% $ 362.3k
Patrick Murphy	Chief Business & Legal Officer	2.5yrs	US$5.33m	0.031% $ 997.1k
Chad Patterson	Chief Commercial Officer	1.9yrs	US$5.77m	0.017% $ 556.5k
Mervin Smith	Executive Vice President of Business Operations	less than a year	データなし	データなし
Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	less than a year	データなし	0.0029% $ 94.8k
Daniel Wilson	Executive VP of Corporate Development & Investor Relations	5yrs	US$3.54m	0.098% $ 3.2m
Douglas Devine	Executive Advisor	1.3yrs	US$2.72m	0.055% $ 1.8m
Sumi Shrishrimal	Executive VP & Chief Risk Officer	2.1yrs	データなし	0.075% $ 2.4m
Stephanie Zhadkevich	Director of Investor Relations	no data	データなし	データなし

2.0yrs

平均在職期間

45yo

平均年齢

経験豊富な経営陣: 0A7Lの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Quentin Blackford	President	2.4yrs	US$16.60m	0.23% $ 7.5m
Ralph Snyderman	Independent Director	6.9yrs	US$233.12k	0.032% $ 1.1m
Michael Mirro	Medical Director & Member of Scientific Advisory Board	no data	データなし	データなし
Bruce Bodaken	Independent Director	6.9yrs	US$240.25k	0.030% $ 985.4k
Abhijit Talwalkar	Independent Chairman	8.1yrs	US$286.74k	0.034% $ 1.1m
R. Mead	Medical Director & Member of Scientific Advisory Board	no data	データなし	データなし
James Quinn	Member of Scientific Advisory Board	no data	データなし	データなし
Cathleen Noel Merz	Independent Director	6.2yrs	US$230.62k	0.019% $ 602.6k
Mark Rubash	Independent Director	8.3yrs	US$248.12k	0.034% $ 1.1m
Mehdi Razavi	Medical Director & Member of Scientific Advisory Board	no data	データなし	データなし
Karen Ling	Independent Director	2.6yrs	US$239.97k	0.020% $ 664.9k
Jay Alexander	Medical Director & Member of Scientific Advisory Board	no data	データなし	データなし

6.9yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: 0A7Lの取締役会は経験豊富であると考えられます ( 6.9年の平均在任期間)。

iRhythm Technologies マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

President recently sold US$3.0m worth of stock

Insider recently sold US$746k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

Executive VP & Chief Risk Officer recently sold US$124k worth of stock

COO & Secretary recently sold US$415k worth of stock

Recent updates

iRhythm Technologies, Inc. Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

First quarter 2024 earnings released: US$1.47 loss per share (vs US$1.29 loss in 1Q 2023)

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q1, 2024 Results on May 02, 2024

New minor risk - Profitability

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

New minor risk - Shareholder dilution

President recently sold US$3.0m worth of stock

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against iRhythm Technologies, Inc

iRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024

iRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events

Insider recently sold US$746k worth of stock

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.89 loss per share (vs US$0.71 loss in 3Q 2022)

iRhythm Technologies, Inc. to Report Q3, 2023 Results on Nov 02, 2023

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

iRhythm Technologies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.80 loss in 2Q 2022)

Now 20% undervalued

iRhythm Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

iRhythm Technologies, Inc. Announces Director Appointments

Executive VP & Chief Risk Officer recently sold US$124k worth of stock

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$1.29 loss per share (vs US$1.71 loss in 1Q 2022)

Now 20% undervalued

COO & Secretary recently sold US$415k worth of stock

Now 21% undervalued

Full year 2022 earnings released: US$3.88 loss per share (vs US$3.46 loss in FY 2021)

iRhythm Technologies, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Chief Legal Counsel recently sold US$182k worth of stock

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2022

iRhythm Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022

iRhythm Technologies, Inc. Reiterates Revenue Guidance for the Year 2022

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.59 loss in 2Q 2021)

iRhythm Technologies, Inc. Appoints Brice Bobzien as Chief Financial Officer, Effective August 8, 2022

iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System

iRhythm Technologies, Inc. Announces Management Changes

Executive Vice President of Strategy recently sold US$156k worth of stock

Independent Director recently sold US$56k worth of stock

First quarter 2022 earnings released: US$1.71 loss per share (vs US$0.95 loss in 1Q 2021)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

iRhythm Technologies, Inc. to Report Q1, 2022 Results on May 05, 2022

iRhythm Technologies, Inc., Annual General Meeting, May 26, 2022

iRhythm Technologies, Inc. Announces the Results of Three Clinical Research Studies Presented At the American College of Cardiology’s 71 Annual Scientific Session & Expo

Consultant & Director recently sold US$904k worth of stock

iRhythm Technologies, Inc. Announces the Results of the KP-Rhythm2 Study

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

COO, CFO & Secretary recently sold US$557k worth of stock

iRhythm Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.17 loss in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.75 loss in 2Q 2020)

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2021

iRhythm Technologies, Inc.(NasdaqGS:IRTC) dropped from Russell 2000 Growth-Defensive Index

iRhythm Technologies Continues to Fuel Innovation in Cardiac Monitoring and Unveils Two FDA Clearances for Superior Patient Care

iRhythm Technologies, Inc. Provides Earnings Guidance for the First Quarter of 2021

First quarter 2021 earnings released: US$0.95 loss per share (vs US$0.34 loss in 1Q 2020)

Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against iRhythm Technologies, Inc

Full year 2020 earnings released: US$1.58 loss per share (vs US$2.16 loss in FY 2019)

Revenue beats expectations

Study Published in Jama Cardiology Finds Zio by iRhythm Proactively Identifies Atrial Fibrillation, Increases Detection Tenfold

CEO報酬分析

マネジメント基準チェック /24